| Name | Title | Contact Details |
|---|
PureGels Nutraceuticals is a Downey, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ENGAGE Healthcare Business Services is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VHA Inc. is a national network of not-for-profit health care organizations working together to improve performance and efficiency in clinical, financial and operational management. Since 1977, when VHA established the first hospital membership organization, the company has applied its knowledge in analytics, contracting, consulting and network development to help members and customers achieve their strategic objectives. In 2012, VHA delivered $1.9 billion in savings and additional value to members. Serving 5,100 health system members and affiliates, VHA represents more than a quarter of the nation's hospitals. VHA also serves more than 118,000 non-acute health care customers enterprise-wide. VHA is based in Irving, Texas, and has 12 regional offices across the U.S. VHA, together with UHC, owns Novation, a supply chain company, and aptitude™ , the health care industry's first online direct contracting market. VHA also owns Provista, a supply chain company serving the non-acute market as well as hospitality, education and corporate markets.
Better Health Group is a national primary care platform that enables providers to shift focus to value-based care. They take a proactive approach by focusing on preventing disease rather than just treating symptoms.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.